offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff "semaglutide" Novo Nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded "semaglutide" drugs and their foreign illicit active ingredients PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of initiatives to further support patient access to authentic, FDA-approved Wegovy (semaglutide) injection 2.4 mg
Legal Recourse and Mass Tort Actions The emergence of adverse effects associated with semaglutide drugs has led to the initiation of mass tort actions against their manufacturers
The most commonly reported side effects relate to digestion, such as nausea, diarrhoea and indigestion
Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects
Furthermore, research was published explaining how human plasma DSIP decreases at the point of sleep regardless of the timing of the sleep, i.e, a persons usual sleep time, or a later sleep time, natural DSIP still decreased
